Adma Biologics Inc

Adma Biologics Inc ADMA

Dividend Summary



There have not been any declared dividends recently.

Latest Dividends
Summary Previous dividend Next dividend
Status
Type
Per share
Declaration date
Ex-div date
Pay date

Enter the number of Adma Biologics Inc shares you hold and we'll calculate your dividend payments:

Previous Payment
Next Payment
Forecast Accuracy
We have not made any dividend predictions for Adma Biologics Inc
Dividend Yield Today
0.0%
The dividend yield is calculated by dividing the annual dividend payment by the prevailing share price
The table below shows the full dividend history for Adma Biologics Inc
Status Type Decl. date Ex-div date Pay date Decl. Currency Forecast amount Decl. amount Accuracy
There are no Adma Biologics Inc dividends.
Year Amount Change
2006 0.0c
2007 0.0c
0%
2008 0.0c
0%
2009 0.0c
0%
2010 0.0c
0%
2011 0.0c
0%
2012 0.0c
0%
2013 0.0c
0%
2014 0.0c
0%
2015 0.0c
0%
2016 0.0c
0%
2017 0.0c
0%
2018 0.0c
0%
2019 0.0c
0%
2020 0.0c
0%
2021 0.0c
0%
2022 Sign Up Required

Adma Biologics Inc Optimized Dividend Chart

The chart below shows the optimized dividends for this security over a rolling 12-month period.
Dividend Yield Today
0.0%
Optimized Yield
Sign Up Required
52 Week High
0.0% on 04 December 2021
52 Week Low
0.0% on 04 December 2021
Next Ex-Div-Date Countdown
Sign Up Required

About Adma Biologics Inc

ADMA Biologics, Inc. is a biopharmaceutical company. It develops, manufactures, and markets specialty plasma-based biologics for the treatment and prevention of infectious diseases. It is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its patients include immune-compromised individuals who suffer from an underlying immune deficiency disorder and immune-suppressed for medical reasons. Its product candidates include BIVIGAM, an Intravenous Immune Globulin (IVIG) product indicated for the treatment of Primary Humoral Immunodeficiency (PI); ASCENIV an IVIG product indicated for the treatment of PI, and Nabi-HB which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen (HBsAg). Its ADMA BioCenters subsidiary operates source plasma collection facilities in the United States. Its Plasma Collection Centers segment, provides a portion of its blood plasma for the manufacture of its products candidates.

Sector
Pharmaceuticals & Biotechnology
Country
United States
Share Price
$3.36 (yesterday's closing price)
Shares in Issue
197 million
Market Cap
$661mn
CADI
The Consecutive Annual Dividend Increases - the number of years this company has been increasing its dividends
0
Market Indices
none
No articles found